BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematologic Malignancy
Conditions
Hematologic Malignancy
Trial Timeline
May 1, 2015 → May 16, 2019
NCT ID
NCT02352558About BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib
BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib is a phase 1 stage product being developed by Sumitomo Pharma for Hematologic Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT02352558. Target conditions include Hematologic Malignancy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02352558 | Phase 1 | Completed |
Competing Products
20 competing products in Hematologic Malignancy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| RLYB116 for Injection | Rallybio | Phase 1 | 25 |
| DS3790a + Combination drug + Combination drug | Daiichi Sankyo | Phase 1/2 | 41 |
| Isavuconazole | Astellas Pharma | Phase 2 | 52 |
| isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral | Astellas Pharma | Phase 1 | 33 |
| DSP-5336 + [14C]-DSP-5336 | Sumitomo Pharma | Phase 1 | 33 |
| Venetoclax + ethinyl estradiol/levonorgestrel | AbbVie | Phase 1 | 33 |
| ABT-888 + Temozolomide | AbbVie | Phase 1 | 33 |
| ABBV-101 | AbbVie | Phase 1 | 33 |
| elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection | AbbVie | Phase 2 | 52 |
| Capivasertib + Rabeprazole | AstraZeneca | Phase 1 | 33 |
| AZD9829 + AZD9829 | AstraZeneca | Phase 1/2 | 41 |
| ridaforolimus | Merck | Phase 2 | 52 |
| Pembrolizumab/vibostolimab coformulation | Merck | Phase 2 | 52 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Ondansetron + Aprepitant | Merck | Phase 2 | 52 |
| Nemtabrutinib | Merck | Phase 2 | 52 |
| ARQ 621 | Merck | Phase 1 | 33 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Pelabresib | Novartis | Phase 3 | 77 |